Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018

From Startup Anika Therapeutics

Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-participate-2018-morgan-stanley-global-healthcare

BEDFORD, Mass.–(BUSINESS WIRE)–Sep. 5, 2018–
Anika
Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic
and regenerative medicines company specializing in therapeutics based on
its proprietary hyaluronic
acid (“HA”) technology, today announced that its President
and Chief Executive Officer, Joseph Darling, and Chief Financial
Officer, Sylvia Cheung, will participate in a fireside chat at the 2018
Morgan Stanley Global Healthcare Conference on Wednesday, September 12,
2018 at 8:10 am ET. The conference is being held at The Grand Hyatt
Hotel in New York, NY.

A live audio webcast of the session may be accessed via the “Investor
Relations” section of Anika’s website at www.anikatherapeutics.com.
An audio archive of the session will also be available on the website.

About Anika Therapeutics, Inc.
Anika
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic
and regenerative medicines company based in Bedford, Massachusetts.
Anika is committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically meaningful
therapies along the continuum of care, from palliative pain management
to regenerative tissue repair. The Company has over two decades of
global expertise developing, manufacturing, and commercializing more
than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®,
MONOVISC®,
and CINGAL®,
which alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180905005839/en/
Source: Anika Therapeutics, Inc.

For Investor Inquiries:Anika Therapeutics, Inc.Sylvia
Cheung, 781-457-9000Chief Financial OfficerorFor Media
Inquiries:Pure Communications, Inc.Sonal Vasudev,
917-523-1418sonal@w2ogroup.com

Please visit their site for more information: Anika Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-09-06 19:58:30